Your Twin learns with you

30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Reetta Kälviäinen

Country flagFinland

Research Interests

Explore related searches

Articles (7)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Objective Progressive myoclonic epilepsy type 1 (EPM1) is caused by biallelic alterations in the CSTB gene, most commonly dodecamer repeat expansions. Although transcranial magnetic stimulation (TMS)–induced long‐interval intracortical inhibition (LICI) was previously reported to be normal in EPM1, short‐interval intracortical inhibition (SICI) was reduced. We explored the association between these measures and the clinical and genetic features in a separate group of patients with EPM1. Methods TMS combined with electromyography was performed under neuronavigation. LICI was induced with an inter‐stimulus interval (ISI) of 100 ms, and SICI with ISIs of 2 and 3 ms, and their means (mSICIs) were expressed as the ratio of conditioned to unconditioned stimuli. LICI and mSICI were compared between patients and controls. Nonparametric correlation was used to study the association between inhibition and parameters of clinical severity, including the Unified Myoclonus Rating Scale (UMRS); among patients with EPM1 due to biallelic expansion repeats, also the association with the number of repeats was assessed. Results The study protocol was completed in 19 patients (15 with biallelic expansion repeats and 4 compound heterozygotes), and 7 healthy, age‐ and sex‐matched control participants. Compared to controls, patients demonstrated significantly less SICI (median mSICI ratio 1.18 vs 0.38; p < .001). Neither LICI nor SICI was associated with parameters of clinical severity. In participants with biallelic repeat expansions, the number of repeats in the more affected allele (greater repeat number [GRN]) correlated with LICI (rho = 0.872; p < .001) and SICI (rho = 0.689; p = .006). Significance Our results strengthen the finding of deranged γ‐aminobutyric acid (GABA)ergic inhibition in EPM1. LICI and SICI may have use as markers of GABAergic impairment in future trials of disease‐modifying treatment in this condition. Whether a higher number of expansion repeats leads to greater GABAergic impairment warrants further study.

Year:

2022

Collaborators (6)

Leena Kämppi

University of Helsinki

FINLAND
View details

Andreas Brunklaus

University of Glasgow

UNITED KINGDOM
View details

Amy McTague

University College London

UNITED KINGDOM
View details

Guido Rubboli

Københavns Universitet

DENMARK
View details

Sebastian Ortiz De la Rosa

University of Southern Denmark

DENMARK
View details

Petro Julkunen

Professor

University of Eastern Finland

FINLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.